The clinical applications of fluorouracil in ophthalmic practice

被引:63
作者
Abraham, Lekha M.
Selva, Dinesh
Casson, Robert
Leibovitch, Igal
机构
[1] Univ Adelaide, Royal Adelaide Hosp, Dept Ophthalmol & Visual Sci, Glaucoma Serv,S Australian Inst Ophthalmol, Adelaide, SA 5000, Australia
[2] Univ Adelaide, Royal Adelaide Hosp, Oculoplast & Orbital Unit, S Australian Inst Ophthalmol, Adelaide, SA 5000, Australia
[3] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia
[4] Univ Adelaide, Dept Surg, Adelaide, SA 5001, Australia
[5] Tel Aviv Univ, Tel Aviv Med Ctr, Oculoplast & Orbital Div, Dept Ophthalmol, IL-69978 Tel Aviv, Israel
关键词
D O I
10.2165/00003495-200767020-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluorouracil (5-fluorouracil, 5-FU) is a pyrimidine analogue that was originally known for its widespread use as an anticancer drug. The ability of 5-FU to reduce fibroblastic proliferation and subsequent scarring has made it an important adjunct in ocular and periorbital surgeries. It is used in primary glaucoma filtering surgeries and in reviving failing filtering blebs, in dacryocystorhinostomy, pterygium surgery, and in vitreoretinal surgery to prevent proliferative vitreoretinopathy. In addition, 5-FU is also gaining recognition in the treatment and surgical management of ocular surface malignancies like ocular surface squamous neoplasia; however, the specific action of the drug on highly proliferating cells limits its use in primary acquired melanosis of the conjunctiva. When applied topically, this drug has a low rate of sight-threatening adverse effects, is inexpensive, and is easy to administer, making it an important tool in enhancing the success rate in ophthalmic surgery and in reducing the recurrence of ocular surface neoplasia.
引用
收藏
页码:237 / 255
页数:19
相关论文
共 130 条
[21]   POSTOPERATIVE IRRADIATION FOR PTERYGIUM - GUIDELINES FOR OPTIMAL TREATMENT [J].
BRENNER, DJ ;
MERRIAM, GR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (03) :721-725
[22]   Needle revision of failing and failed trabeculectomy blebs with adjunctive 5-fluorouracil survival analysis [J].
Broadway, DC ;
Bloom, PA ;
Bunce, C ;
Thiagarajan, M ;
Khaw, PT .
OPHTHALMOLOGY, 2004, 111 (04) :665-673
[23]  
Budenz DL, 1999, OPHTHALMIC SURG LAS, V30, P367
[24]  
Cantor L, 1998, J GLAUCOMA, V7, P240
[25]   An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy [J].
Cardillo, JA ;
Farah, ME ;
Mitre, J ;
Morales, PH ;
Costa, RA ;
Melo, LAS ;
Kuppermann, B ;
Jorge, R ;
Ashton, P .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (09) :1201-1205
[26]  
CHABNER BA, 1996, GOODMAN GILMANS PHAR, P1247
[27]   THE EFFECT OF TRIAMCINOLONE ACETONIDE ON A REFINED EXPERIMENTAL-MODEL OF PROLIFERATIVE VITREORETINOPATHY [J].
CHANDLER, DB ;
ROZAKIS, G ;
DEJUAN, E ;
MACHEMER, R .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1985, 99 (06) :686-690
[28]   A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy [J].
Charteris, DG ;
Aylward, GW ;
Wong, D ;
Groenewald, C ;
Asaria, RHY ;
Bunce, C .
OPHTHALMOLOGY, 2004, 111 (12) :2240-2245
[29]   Randomized, controlled study of low-dose 5-fluorouracil in primary trabeculectomy [J].
Chaudhry, IA ;
Pasha, MA ;
O'Connor, DJ ;
Weitzman, ML ;
Caprioli, J .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2000, 130 (06) :700-703
[30]  
COSTA VP, 1993, OPHTHALMIC SURG LAS, V24, P152